#1 Clinical Trials Search in Europe

Regn7075

REGN7075 is an investigational drug currently being studied in clinical trials for the treatment of advanced solid tumors. These trials aim to evaluate the safety, tolerability, and effectiveness of REGN7075 when used alone or in combination with other cancer treatments, such as cemiplimab and chemotherapy. The studies focus on various types of advanced cancers, including non-small cell lung cancer, colorectal cancer, and head and neck squamous cell carcinoma, among others.

Table of Contents

What is REGN7075?

REGN7075 is an investigational drug being studied for the treatment of various advanced cancers[1]. It is classified as an EGFRxCD28 costimulatory bispecific antibody, which means it is designed to target two specific proteins in the body simultaneously[1]. This unique approach aims to enhance the body’s immune response against cancer cells.

How Does REGN7075 Work?

REGN7075 works by targeting two important proteins:

  • EGFR (Epidermal Growth Factor Receptor): This protein is often overexpressed in cancer cells and helps them grow and divide.
  • CD28: This protein is found on T cells (a type of immune cell) and helps activate them.

By binding to both EGFR on cancer cells and CD28 on T cells, REGN7075 aims to bring these cells closer together. This interaction is designed to stimulate the T cells to recognize and attack the cancer cells more effectively[1].

What Cancers Does REGN7075 Target?

REGN7075 is being investigated for the treatment of various advanced solid tumors[1]. Clinical trials are focusing on several specific cancer types, including:

  • Triple Negative Breast Cancer (TNBC): A type of breast cancer that lacks certain receptors commonly found in other breast cancers.
  • Cutaneous Squamous Cell Carcinoma (CSCC): A type of skin cancer.
  • Non-Small Cell Lung Cancer (NSCLC): The most common type of lung cancer.
  • Head and Neck Squamous Cell Carcinoma (HNSCC): Cancers that begin in the cells that line the mouth, nose, and throat.
  • Colorectal Cancer (CRC): Cancer that starts in the colon or rectum.

These cancers are being studied in various stages and with different characteristics, such as the presence of specific mutations or metastases (spread to other parts of the body)[1].

Clinical Trials and Research

REGN7075 is currently being evaluated in clinical trials to determine its safety and effectiveness. These trials are designed to answer important questions about the drug, including:

  • How safe is REGN7075 when used alone or in combination with other treatments?
  • What is the best dose of REGN7075 to use?
  • How effective is REGN7075 at treating different types of cancer?
  • How does REGN7075 work in the body?
  • How much of the drug remains in the blood over time?

Researchers are also looking at how REGN7075 affects the growth and spread of tumors[1].

Combination Therapy with Cemiplimab

Many of the clinical trials are studying REGN7075 in combination with another drug called cemiplimab (also known as REGN2810 or Libtayo)[1][2]. Cemiplimab is an immunotherapy drug that helps the immune system recognize and attack cancer cells. By combining REGN7075 with cemiplimab, researchers hope to enhance the overall anti-cancer effect.

Some studies are also exploring the combination of REGN7075, cemiplimab, and chemotherapy, particularly in patients with non-small cell lung cancer[2].

Administration and Dosing

REGN7075 is administered either through intravenous (IV) infusion (directly into a vein) or subcutaneous (SC) injection (under the skin). The frequency of administration can vary, with some regimens giving the drug every week and others every three weeks[1]. The exact dosing schedule and method of administration may depend on the specific clinical trial and the patient’s individual circumstances.

Potential Side Effects and Safety Monitoring

As REGN7075 is still in the investigational stage, all potential side effects are not yet known. However, clinical trials are closely monitoring for any adverse events, including:

  • Treatment-emergent adverse events (TEAEs)
  • Serious adverse events (SAEs)
  • Immune-related side effects
  • Laboratory abnormalities
  • Infusion-related reactions

Patients in clinical trials are closely monitored for these and other potential side effects to ensure safety[1][2].

Quality of Life Assessments

An important aspect of the REGN7075 clinical trials is assessing how the treatment affects patients’ quality of life. Researchers use various questionnaires to measure factors such as:

  • Overall health status and quality of life
  • Specific cancer-related symptoms
  • Physical functioning
  • Emotional well-being

These assessments help researchers understand not just how effective the treatment is at fighting cancer, but also how it impacts patients’ daily lives and overall well-being[1].

Aspect Details
Drug Name REGN7075
Drug Type EGFRxCD28 costimulatory bispecific antibody
Administration Intravenous (IV) infusion or subcutaneous (SC) injection
Frequency Every week (QW) or every 3 weeks (Q3W)
Combination Therapy Studied with cemiplimab, with or without chemotherapy
Cancer Types Studied Advanced solid tumors, including NSCLC, TNBC, CSCC, HNSCC, CRC
Primary Outcomes Safety, tolerability, adverse events, objective response rate
Secondary Outcomes Drug concentrations, progression-free survival, overall survival, quality of life
Study Duration Up to 5 years

FAQ

  • What is REGN7075? REGN7075 is an investigational drug known as an EGFRxCD28 costimulatory bispecific antibody. It is being studied for the treatment of advanced solid tumors in combination with other cancer treatments.
  • What types of cancers are being studied with REGN7075? REGN7075 is being studied in various advanced solid tumors, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), cutaneous squamous cell carcinoma (CSCC), head and neck squamous cell carcinoma (HNSCC), and colorectal cancer (CRC).
  • How is REGN7075 administered? REGN7075 is administered through intravenous (IV) infusion or subcutaneous (SC) injection. The frequency of administration can be either every week or every three weeks, depending on the study protocol.
  • What are the main goals of the clinical trials involving REGN7075? The main goals of these trials are to determine the safety and tolerability of REGN7075, find the best dose for treatment, and evaluate its effectiveness in treating advanced solid tumors when used alone or in combination with other cancer treatments.
  • What are some of the side effects being monitored in these trials? The trials are monitoring various side effects, including treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs). They are also tracking laboratory abnormalities and the development of anti-drug antibodies.

Ongoing Clinical Trials on Regn7075

  • Study of Cemiplimab, Carboplatin, and Paclitaxel for Adults with Operable Non-Small Cell Lung Cancer

    Recruiting

    2 1 1 1
    Investigated drugs:
    France Germany Spain

  • Study on the Safety and Effectiveness of REGN7075 and Cemiplimab, with or without Chemotherapy, for Patients with Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated drugs:
    France The Netherlands Poland Spain

Glossary

  • REGN7075: An investigational drug known as an EGFRxCD28 costimulatory bispecific antibody, being studied for the treatment of advanced solid tumors.
  • Cemiplimab: A type of immunotherapy drug used in combination with REGN7075 in some clinical trials. It's also known by the brand name Libtayo.
  • Solid Tumors: Abnormal masses of tissue that usually do not contain cysts or liquid areas. Solid tumors may be benign (not cancerous) or malignant (cancerous).
  • Non-Small Cell Lung Cancer (NSCLC): A type of lung cancer that is the most common form of the disease, accounting for about 80-85% of all cases.
  • Triple Negative Breast Cancer (TNBC): A type of breast cancer that tests negative for estrogen receptors, progesterone receptors, and excess HER2 protein.
  • Cutaneous Squamous Cell Carcinoma (CSCC): A common form of skin cancer that develops in the squamous cells that make up the middle and outer layers of the skin.
  • Head and Neck Squamous Cell Carcinoma (HNSCC): A type of cancer that begins in the squamous cells that line the moist, mucosal surfaces inside the head and neck.
  • Colorectal Cancer (CRC): A type of cancer that starts in the colon or rectum.
  • Adverse Events: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Anti-Drug Antibodies (ADA): Antibodies that develop in response to a therapeutic drug, which may affect the drug's effectiveness or cause side effects.

References